Innovent Biologics, Inc. (HKG: 1801)

Innovent Biologics Ratios and Metrics

Market cap in millions HKD. Fiscal year is January - December.

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 6, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	68,022	69,333	51,403	70,547	115,098	33,521
Market Cap Growth	31.40%	34.88%	-27.14%	-38.71%	243.36%	20.57%
Enterprise Value	62,349	63,850	44,899	59,352	109,367	30,495
Last Close Price	41.75	42.75	33.50	48.25	82.05	26.55
PE Ratio	-	-58.79	-20.26	-20.91	-93.36	-16.25
PS Ratio	8.35	10.14	9.98	13.46	25.21	28.61
PB Ratio	5.07	5.02	4.24	5.56	11.04	6.30
P/FCF Ratio	-	-64.78	-16.15	-18.60	-121.65	-14.76
P/OCF Ratio	-	425.78	-23.70	-28.38	-314.98	-18.00
EV/Sales Ratio	7.78	9.34	8.72	11.32	23.96	26.02
EV/EBITDA Ratio	-35.87	-44.99	-13.80	-19.05	-188.25	-15.61
EV/EBIT Ratio	-30.42	-37.06	-12.72	-17.89	-165.28	-14.98
EV/FCF Ratio	-	-59.65	-14.11	-15.65	-115.59	-13.43
Debt / Equity Ratio	0.27	0.29	0.30	0.24	0.14	0.18
Debt / FCF Ratio	-	-3.73	-1.15	-0.81	-1.51	-0.43
Asset Turnover	0.39	0.32	0.27	0.30	0.40	0.16
Inventory Turnover	2.13	1.51	1.00	1.19	1.45	2.94
Quick Ratio	2.42	2.68	2.78	3.27	5.85	4.78
Current Ratio	2.68	3.00	3.29	3.79	6.37	5.23
Return on Equity (ROE)	-11.04%	-8.84%	-20.70%	-28.56%	-14.75%	-38.43%
Return on Assets (ROA)	-5.19%	-5.12%	-11.54%	-12.03%	-3.65%	-17.05%
Return on Capital (ROIC)	-6.60%	-6.49%	-14.57%	-14.81%	-4.46%	-21.44%
Earnings Yield	-2.06%	-1.63%	-4.79%	-4.75%	-1.03%	-5.74%
FCF Yield	-1.54%	-6.19%	-5.38%	-0.82%	-6.78%
Buyback Yield / Dilution	-5.12%	-4.66%	-2.37%	-7.27%	-15.23%	-251.88%
Total Shareholder Return	-5.12%	-4.66%	-2.37%	-7.27%	-15.23%	-251.88%

Source: S&P Capital IQ. Standard template. Financial Sources.